Most of what is written about PCOS and fertility is either a reassurance with nothing behind it or a list of things to buy. The thing that is genuinely hard to find stated plainly is the order — what is tried first, what is tried next, and why one option sits above another.
There is an order. It is in the 2023 international guideline, it is specific, and it is the most useful thing to carry into an appointment, because it tells you what question to ask rather than what to hope for.
This page names no doses and gives no advice about your own situation. It sets out what the guideline recommends, which is a different and more checkable thing.
The mechanism, briefly
The route by which PCOS most often affects fertility is anovulation — cycles in which an egg is not released. That is why irregular or absent cycles are one of the three diagnostic criteria, and it is also why the subject has first-line pharmacological answers at all: a cycle that is not ovulating is a specific problem with specific interventions aimed at it.
It also means the conversation is narrower than “PCOS and fertility” suggests. The guideline’s ovulation induction recommendations apply to anovulatory women with PCOS and no other infertility factors, which is a defined group rather than everyone with the diagnosis.
The order, as published
| Where the guideline puts it | For | |
|---|---|---|
| Letrozole | First-line pharmacological treatment for ovulation induction | Anovulatory PCOS, no other infertility factors |
| Clomiphene citrate | Second-line — alone or with metformin | The same group |
| Metformin | Can be used alone, with the caveat that more effective agents exist | Preferred over clomiphene for metabolic indications, not for ovulation |
| Gonadotrophins, ovarian surgery | Also second-line | Where earlier steps have not worked |
The row that surprises people is the first one, because clomiphene is the drug most have heard of and letrozole is the one most have not.
Why letrozole sits above clomiphene
The guideline recommends letrozole rather than clomiphene citrate, on three outcomes rather than one: ovulation, clinical pregnancy, and live birth rates. Live birth is the one worth noticing — it is the outcome that actually matters and the one many comparisons quietly leave out in favour of something easier to measure.
It also addresses the question that reasonably follows. Comparing the two, the guideline found no difference in rates of fetal abnormality. That is stated because it is the first thing anyone asks about a drug they have not heard of, and because the alternative to stating it is leaving people to find a forum.
The off-label part, which is not what it sounds like
Letrozole is off-label for this purpose in many countries. The guideline says so directly and recommends it first-line anyway, adding that where it is not permitted, other ovulation induction agents should be used.
Off-label means a regulator licensed the drug for something else and has not been asked, or has not agreed, to extend the licence. It is a statement about paperwork and commercial incentive — the drug is old and cheap, and nobody profits from funding a new licence application — not a finding about the drug. Guidelines recommend off-label use routinely when the evidence supports it, which is exactly what has happened here.
This matters practically, because it is why the answer to “why was I offered clomiphene?” can be geography rather than clinical judgement, and that is a reasonable thing to ask about.
Where metformin actually sits
Metformin comes up constantly in this conversation and its position is narrower than its reputation.
The guideline’s line is that metformin alone can be used to improve pregnancy and live birth rates in this group — and that women should be told there are more effective ovulation agents. Clomiphene is preferred over metformin alone where there are no other infertility factors, and clomiphene combined with metformin is an option over metformin alone.
So it is not absent and it is not the answer. Its stronger indication in PCOS remains metabolic, which is a different job from inducing ovulation and gets confused with it because the same drug appears in both conversations.
One step that is not optional
Pregnancy should be excluded before ovulation induction therapy begins. The guideline states it plainly, and it is worth knowing in advance so it does not read as anyone doubting you.
What most articles get wrong
They lead with supplements. The search results on this topic are dominated by things you can buy without a prescription. The guideline’s first-line answer is a prescription medicine, and what it says about inositol — limited clinical benefit, less effective than metformin — is considerably less marketable than the pages selling it.
They treat clomiphene as the default. It is second-line in the current guideline. A page written before 2018 and never revised will still have it first, and most of this subject’s search results were written a long time ago.
They promise. No honest page can tell you what will happen in your case, because the guideline’s recommendations are about a defined group and your clinician knows things about you that no article does. What an article can do is tell you what the published order is, so that a consultation starts further along.
What is worth recording while this is going on
Ovulation induction cycles are tracked by dates, and dates are the thing memory handles worst under stress.
When a cycle started. When medication was taken and for how many days. When a scan or a blood test happened and what it said. Whether anything changed. Across two or three cycles that is a record a clinician can read in thirty seconds, and the alternative is reconstructing it in the appointment from a phone’s photo roll — which is what most people are actually doing, and it costs half the consultation.
None of that makes anything more likely to work. It makes the next conversation about what happened rather than about what anyone can remember.